

University of Groningen

## Lymph node staging in colon cancer

Kelder, Wendy

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2008

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Kelder, W. (2008). *Lymph node staging in colon cancer*. s.n.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

## Chapter 7

### Effects of 5-fluorouracil adjuvant treatment of colon cancer

*W.Kelder<sup>1,2</sup>, G.A.P. Hospers<sup>3</sup>, J.T.M. Plukker<sup>2</sup>*

<sup>1</sup>Department of Surgery, Martini Hospital, Groningen, The Netherlands

<sup>2</sup>Department of Surgery, University Medical Centre, Groningen, The Netherlands

<sup>3</sup>Department of Internal Medicine, Oncology, University Medical Centre, Groningen, The Netherlands

*Expert Review of Anticancer Therapy 2006, 6(5): 785-794*

**Abstract**

Since the late eighties and early nineties, 5-fluorouracil (5-FU) based chemotherapy is the standard adjuvant treatment for stage III colon cancer. After the initial introduction of 5-FU in standard treatment protocols, several changes have been made based on results of randomized studies on various treatment regimens, including new cytotoxic agents. In stage II patients, the role of adjuvant chemotherapy is debatable. However, there might be a role for adjuvant treatment in certain high-risk patients. Following a search of the Medline database, the authors review the results of randomized studies on 5-FU-based adjuvant therapy and discuss future therapeutic options.

## Introduction

### ***Overview of the disease***

Colorectal carcinoma (CRC) is the most common gastro-intestinal malignancy and the second leading cause of cancer related deaths in the world. Each year, worldwide, 500 000 people die of the disease and nearly one million cases are newly diagnosed. The disease is relatively more common in the Western World. Both genetic factors and non-genetic factors, mostly related to the Western lifestyle, contribute to the pathogenesis of colon carcinoma. Genetic predisposition may have a very strong effect in the dominantly inherited cancer syndromes, including familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). The cumulative risk in developed countries is about 5% by the age of 75 years. The number of patients suffering from the disease will probably increase in the future because of aging of the population in developed countries.<sup>1</sup> There is no established way of preventing colon cancer and there is no cost-effective screening method at the moment.<sup>2,3</sup> In general, symptomatic patients are treated as they present themselves. In the end, for half of these patients cure won't be possible. However, approximately 80% of the patients are presented in a stage that is considered to be curable. Lymph node status is still the most important predictor of outcome. However, several molecular biological factors, including *TP53* mutation, the microsatellite instability (MSI) phenotype and TS and DPD mRNA expression seem to play an important role in the success of adjuvant treatment.<sup>4-6</sup> *TP53* has a negative impact on disease-free survival. In patients with high-frequency microsatellite instability (MSI-H) tumors, adjuvant chemotherapy will not significantly improve survival. The 5-year survival rate is 70-80% for patients with node negative disease (stage I/II), but only 45-50 % for those with node positive tumors (stage III).<sup>7</sup> Adenocarcinomas are by far the most common malignant tumors of the large bowel. Other bowel tumors include carcinoid tumors, lymphomas, gastrointestinal stromal cell tumors and metastases of primary tumors elsewhere. All of these tumors are rare. Sixty percent of colorectal cancers arise in the distal part of the large bowel, which is defined as distal to the splenic flexure. In recent years, however, more proximally located tumors have been diagnosed.<sup>8</sup> For the pathologist, colorectal cancer is heterogeneous, both macroscopically and microscopically. The lesions can be exophytic, polypoid or endophytic. Although endophytic lesions may present as a small intraluminal tumor, they usually show an extensive infiltration of the bowel wall. Under the microscope, most cancers are moderately differentiated, gland-forming adenocarcinomas. Mucinous or colloid cancers, which produce extensive amounts of mucin, and signet-ring cell adenocarcinomas, occur much less frequently. The primary treatment for colon cancer is a radical surgical resection.

However, even in radical resections of stage III tumors, small tumor deposits not detected with currently available techniques (micrometastases), are present. Until the 1980's the consensus was, that surgery was the best and only standard treatment. In the early nineties, Moertel et al. showed a clear benefit from multimodality treatment, including adjuvant fluorouracil and levamisole for patients with node-positive disease.<sup>9</sup> Since then, numerous new agents and combinations of therapy have evolved for palliative and adjuvant therapy.<sup>10-20</sup> Despite the favorable prognosis of patients with localized stage II colon cancer without regional lymph node metastasis, 20-30% of these patients will develop recurrent disease, even after apparently curative resection. Generally there are high and low risk groups within stage II colon cancer. One of the therapeutic challenges now and in the future is to find a better way to select these patients and to treat them appropriately with an individualized adjuvant regimen.

### ***Pathology and carcinogenesis***

The great majority of colon cancers develop from colon adenomas or adenomatous polyps. Adenomas are benign neoplastic lesions that arise from the colon epithelium. The origin of adenomas and thus carcinomas is genetic. Colon cancer develops through a multistep process with an accumulation of multiple genetic alterations that are often the cause of a form of genomic instability. The two best known mechanisms of genomic instability are chromosomal instability (CIN) and microsatellite instability (MSI).<sup>5</sup> The CIN pathway is characterized by changes in the cellular genome, such as aneuploidy, multiple chromosomal rearrangements and an accumulation of somatic mutations in several known oncogenes. The loss of function of two tumor suppressor genes, the adenomatous polyposis coli (APC) and the *TP53* gene, is considered to be essential for the initiation and progression of colorectal carcinogenesis in this pathway.<sup>21-24</sup> The CIN phenotype is found in approximately 85% of sporadic colon cancers.<sup>5</sup> The remaining 15% of colorectal cancers display a phenotype with small insertions and deletions mainly in repetitive sequences (microsatellites). This form of genetic destabilization is most commonly caused by the loss of the DNA mismatch-repair function and is referred to as the microsatellite-instability pathway. The phenotype of tumors with this defect is termed the high-frequency-microsatellite-instability phenotype (MSI-H).<sup>5,25-29</sup> Distinct clinical and pathological features of colorectal tumors arising from these two separate mutational pathways have been identified. Mutations in the *TP53* gene are associated with an aggressive tumor growth and

subsequent reduced survival.<sup>5</sup> MSI-H is observed more frequently in colon cancers that occur proximal to the splenic flexure. These MSI-H tumors mostly exhibit poor differentiation, mucinous cell type and peritumoral lymphocytic infiltration.<sup>27,29</sup> They have also been associated with a larger size of the primary tumor and a more favorable stage distribution.<sup>30</sup> Patients with the MSI-H phenotype have longer survival than stage-matched patients with chromosomal instability (CIN) tumors.<sup>29-31</sup> There are two well-known dominantly inherited cancer syndromes named familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC). HNPCC is the most common hereditary cancer syndrome. It is inherited in an autosomal dominant manner. The prevalence of HNPCC in newly diagnosed colon cancer patients is 2-4%. Most tumors in HNPCC are characterized by microsatellite instability of tumor DNA (MIN-pathway).<sup>28</sup> A diagnosis of HNPCC should be suspected when patients with colon cancers have a positive family history of HNPCC related cancers, especially if the diagnosis was made before the age of 50 years. FAP is an autosomal dominantly inherited disorder characterized by the development of hundreds or thousands of adenomatous colorectal polyps during adolescence and early adulthood. Malignant transformation will occur in one or more of these polyps and invasive cancer will develop in most patients before the age of 40. The disease is due to mutations in the APC-gene (CIN-pathway).<sup>23</sup> Less than 1% of colon cancers are due to FAP.

### ***Disease staging***

Accurate staging of colon cancer is essential to clinical decision making and to prognosis. The American Joint Committee on Cancer (AJCC) has designated staging of cancer by the Tumor Node Metastasis (TNM) classification (Box 1).<sup>32</sup> T indicates the progressive degree (1-4) of invasion of the tumor into the bowel wall. N represents the nodal involvement and M indicates distant metastasis. Disease prognosis (without chemotherapy) derived from this staging process is shown in Box 2.

Box 1. TNM Staging

T	Primary tumor
T <sub>0</sub>	No evidence of primary tumor
T <sub>is</sub>	Carcinoma in situ
T <sub>1</sub>	Tumor invasion of submucosa
T <sub>2</sub>	Tumor invasion of muscularis propria
T <sub>3</sub>	Tumor invasion of subserosal fat
T <sub>4</sub>	Tumor invasion of other organs or structures and/or perforation of the visceral peritoneum
N <sub>0</sub>	No lymph node metastases
N <sub>1</sub>	Metastases in 1 to 3 regional lymph nodes
N <sub>2</sub>	Metastases in 4 or more regional lymph nodes
M <sub>0</sub>	No distant metastases
M <sub>1</sub>	Distant metastases

Box 2. Stage grouping for colon cancer and prognosis

pTNM	Stage (AJCC)	5-year survival rate (%)
T <sub>1-2</sub> , N <sub>0</sub> , M <sub>0</sub>	I	90
T <sub>3-4</sub> , N <sub>0</sub> , M <sub>0</sub>	II	80
T <sub>1-4</sub> , N <sub>1-2</sub> , M <sub>0</sub>	III	50
T <sub>1-4</sub> , N <sub>1-2</sub> , M <sub>1</sub>	IV	5

**THERAPEUTIC APPROACHES**

***Overall patient management***

The prognosis of colon cancer is related to the degree of penetration of the tumor through the bowel wall and the presence or absence of lymph node involvement and distant metastases. Curative treatment involves a multi-modality approach, in which surgery is an essential part. Cure can be achieved in approximately 50% of resected patients without adjuvant chemotherapy.<sup>33</sup> Adjuvant chemotherapy is routinely administered when lymph node metastases are present. In case of severe co-morbidity or extensive metastatic

disease, local palliative treatment modalities are frequently applied. This includes stenting for bowel obstruction and radiotherapy for bleeding and pain.<sup>34,35</sup> Following curative intended treatment of colon cancer, periodic evaluations in selected groups may lead to the early identification and management of asymptomatic recurrent disease.

### ***Role of surgery and pathology***

As already mentioned surgery remains the principal treatment modality for stage I to III colon tumors. The extent of the resection is determined by its location within the regional lymph drainage area. For tumors in the right colon (cecum/ascending colon) a right hemicolectomy is performed. This includes resection of the last 10 cm of the terminal ileum and part of the transverse colon with ligation of the ileocolic artery, right colic artery and the right branch of the middle colonic artery. For tumors in or just distal of the hepatic flexure, a right extended hemicolectomy should be performed. This includes ligation of both branches of the middle colic artery. The whole transverse colon is resected when a tumor is located in the transverse colon. Tumors in the splenic flexure or the descending colon are usually treated by a left hemicolectomy, including the area supplied by the left colic artery and left branch of the middle colic artery. For sigmoid tumors a sigmoid resection is performed during which the superior rectal artery and its branching sigmoidal arteries are ligated. To prevent spill of tumor cells due to mobilization of the tumor, the 'no-touch' technique was developed. It should be noted that this is not a standard procedure in various countries. It involves early ligation (before mobilization) of the feeding artery and central vein. In a prospective study no significant survival benefit of this technique was shown, although it did show a decreased incidence of liver metastases.<sup>36</sup> Treatment of rectal tumors is beyond the scope of this review. Regional lymph nodes are removed en bloc with the resected colon. For adequate staging and treatment of patients with colon cancer, a meticulous histological examination of at least 12 nodes harvested by pathological analysis is warranted according international guidelines.<sup>32</sup>

### ***Role and biological basis of fluorouracil based adjuvant chemotherapy***

Thymidylate synthase (TS) has been used as a target for cancer chemotherapy in the development of fluoropyrimidines such as 5-fluorouracil (5-FU). However, the precise



mechanism by which TS inhibition leads to cell death is still not completely resolved.<sup>37</sup> TS inhibition results in depletion of dTTP, an essential precursor for DNA, and an increase in dUTP. This results in the so-called thymine-less death due to misincorporation of dUTP into DNA. Its excision, catalyzed by uracil-DNA glycosylase, results in DNA damage. Both this imbalance in dTTP/dUTP and DNA damage can result in induction of downstream events, leading to apoptosis.<sup>37</sup> On the other hand a specific interaction exists between oncogenes like *TP53* and *TS*. These complex indirect and direct interactions between oncogenes and *TS* may have as yet unclear clinical implications, since most data are based on in vitro or in vivo studies and some results are contradictory. Randomized trials in the 1980s demonstrated that fluorouracil (FU)-based adjuvant therapy could decrease the chance of death by approximately 30%.<sup>9,38,39</sup> Since then, FU-based adjuvant therapy is recommended for all medically fit patients with completely resected stage III colon cancer. For stage I patients, there are no relevant studies on the use of adjuvant therapy. The benefit of adjuvant therapy for patients with stage II colon cancer has long been an area of controversy. However, consensus guidelines on this subject have been published recently.<sup>40</sup> We will further discuss the use of adjuvant therapy in the subsequent stages of disease in the next paragraphs.

### ***Stage III***

In 1990, as mentioned before, Moertel and coworkers showed that fluorouracil (FU)-based therapy decreased the chance of death in stage III patients by approximately 30%, with a greater than 10% absolute benefit in 5-year survival.<sup>9</sup> They added levamisole, an antihelminthic immunomodulator, to the FU regimen. Later studies showed that the inclusion of levamisole in chemotherapy regimens for colorectal cancer does not delay recurrence or improve survival compared to the combination of 5-FU with leucovorin (Mayo regimen).<sup>10,41</sup> The addition of folinic acid or leucovorin (LV) seems to potentiate the effects of FU. The supplementation of the intracellular reduced folate pool by folinic acid prolongs the competitive inhibition of TS by FU.<sup>42</sup> The benefits of the combination FU and leucovorin were supported by several studies.<sup>15,43,44</sup> The IMPACT trial published in 1995 demonstrated a disease free survival of 71% with the FU/leucovorin combination with an overall survival of 83%.<sup>43</sup> The Quick and Simple and Reliable (Quasar) study in 3239 stage II and III colon and rectal cancer patients, randomizing to either observation or bolus 5-FU plus leucovorin at low or high dose, or 5-FU plus levamisole, showed that higher dose

folinic acid produced no extra benefit over low-dose folinic acid with a significant survival benefit of 3% in the treatment group ( $p=0.02$ ).<sup>10</sup> Survival rates were 70% with 3-year recurrence rates around 36%. These results were confirmed by Link et al who showed a 5-year overall survival rate of 60,5% for stage III patients treated with FU and levamisole versus 72 % if folinic acid was added to this schedule.<sup>15</sup> Furthermore, in the Intergroup 0089 study on 3759 colon cancer patients, 80% of whom were in stage III and 20% in high risk stage II, the 5-FU/low-dose LV (Mayo scheme) proved to be equivalent to 5-FU/ high-dose LV (Roswell Park scheme). Based on these studies and the relative high neurotoxicity of levamisole, which was standard treatment in the early 90's, this drug was abandoned in favor of leucovorin.<sup>45</sup> The oral fluoropyrimidines capecitabine and tegafur-uracil (UFT)/LV generate fluorouracil preferentially in tumor tissue with an equal activity as 5-FU/LV. The final stage of conversion to fluorouracil is catalyzed by thymidine phosphorylase, which is appreciably more active in tumor than healthy tissue. Twelves et al found that oral capecitabine (Xeloda) is an effective and at least equivalent alternative to intravenous FU plus leucovorin in the adjuvant treatment of stage III colon cancer. In addition, it was associated with significantly fewer adverse events than FU plus leucovorin.<sup>20</sup> An equal effect was found for UFT/LV compared to FU/LV.<sup>46</sup> Treatment of advanced CRC has dramatically been improved in the last decade due to the development of new treatment options, including irinotecan (CPT11) and oxaliplatin (L-OHP). Irinotecan is a semisynthetic camptothecin which inhibits topoisomerase I, impeding DNA uncoiling which leads to double-stranded DNA breaks. Oxaliplatin is a platinum-based drug, forming cross-linking adducts, which blocks DNA replication and transcription. Combination therapy of FU/leucovorin with irinotecan or oxaliplatin are effective in stage IV colon cancer, which will be discussed later.<sup>47</sup> Based on the results in advanced disease these new strategies have been used in an adjuvant setting in stage II/III colon cancer patients. However, in stage III colon cancer, the combination of irinotecan with an IV-bolus scheme of FU/leucovorin showed no survival benefit to FU/leucovorin alone.<sup>48</sup> From studies in stage IV patients treated with this combination scheme, it is known that the FU should be administered in a continuous infusion.<sup>49</sup> The results of this FOLFIRI scheme in stage III patients as an adjuvant therapy (Pan European Trial in Adjuvant Colon Cancer: PETACC-3 study;  $n=2111$  pts) have not been published yet. Preliminary data show insufficient effect of the FOLFIRI schedule in stage III colon cancer, with a 3-year disease-free survival of 59,9% and 62,9% in FU/LV and FU/LV/Irinotecan, respectively.<sup>50</sup> Irinotecan seems to have a more additive effect with FU/LV, while oxaliplatin has a more synergistic effect. The Multicenter International Study of Oxaliplatin/5-FU/LV in Adjuvant Treatment of Colon Cancer (MOSAIC) trial included 2246

patients with stage II (40%) and III (60%) colon cancer. It evaluated the efficacy of adjuvant treatment with FU/leucovorin plus oxaliplatin (FOLFOX 4 schedule) versus FU/leucovorin alone. The DFS in the FOLFOX 4 schedule was 85,1% vs 81,3 in the FU/LV schedule. The absolute survival benefit for the FOLFOX schedule was 6,6%.<sup>51</sup> These results were confirmed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) C-07 study which randomly assigned for LV/5-FU alone or combined with oxaliplatin (FLOX) in which 5-FU was given as bolus.<sup>52</sup> This study showed a significant better DFS at 3 years in the FLOX-group (76.5% vs 71.6%, p=0,04) and a 23% reduction in recurrence risk. Based on the above mentioned results FOLFOX became the treatment of choice in the adjuvant setting, although the incidence of myelosuppression and neurotoxicity is relatively higher compared to 5-FU/LV alone. These studies also suggest oxaliplatin to be of benefit independent of 5-FU/LV administration. Whether the substitution of 5-FU/LV by oral alternative equivalents including capecitabine will be beneficial is currently under investigation as first-line therapy.<sup>53</sup> Results of the major trials are summarized in table 1.

Table 1. Results of FU based adjuvant therapy in stage II and III colon cancer

Treatment	Disease stage	Number of patients	Disease free survival rate (%)*	p-value	Ref
None vs FU/levamisole(Lev)	II and III	1269	47 vs 63	<0,0001	9
None vs FU/leucovorin(LV)	II and III	1526	62 vs 71	<0,0001	38
FU/Lev vs FU/Lev/LV	II and III	891	60 vs 70	<0,01	39
FU/Lev/LV vs FU/LV	I,II,III	4927	63 vs 65	0,06	10
FU/Lev vs FU/Lev/LV	III	855	57 vs 66	0,0004	15
FU/LV vs capecitabine	III	1987	60 vs 64	0,12	20
FU/LV vs FU/LV/oxaliplatin	II and III	2246	72,9 vs 78,2	0,002	11

\*3- or 5-year survival

### ***Stage II***

As mentioned in the introduction, the benefit of adjuvant therapy for patients with stage II colon cancer has long been an area of controversy. Too few stage II patients have been included in most trials to determine whether they derive a small benefit from FU-based postoperative therapy. The trials that include higher numbers of patients show conflicting results.<sup>54-58</sup> The results of the trials are summarized in table 2. The varying results between the trials might be explained by differences in the study populations. It is possible that there is a difference between the studies in the proportion of patients with poor prognostic indicators such as bowel obstruction, perforation, adhesion to adjacent organs and in those cases with <12 lymph nodes examined in the pathology report. Patients with these characteristics are classified as high risk patients. Because the number of high risk stage II patients is usually low in the study population, it is unlikely that significant survival differences are found when administering chemotherapy. In the NSABP pooled analysis a 5% disease free survival difference was found after adjuvant therapy between high and low risk stage II patients.<sup>56</sup> Andre et al, using the FOLFOX schedule, also found a 5% disease free survival difference. Both studies did not reach significance, probably because of insufficient numbers. The American Society of Clinical Oncology (ASCO) recently published guidelines on this subject, in which the routine use of adjuvant chemotherapy is not supported in node-negative patients. However, they did find indirect evidence of benefit for patients with high-risk disease.<sup>40</sup> We have to refine the category of patients with stage II colon cancer who may benefit from adjuvant treatment. At least 12 lymph nodes have to be examined to consider the tumor as node negative. Whether the sentinel node procedure will be valuable is still a matter of debate

Table 2. Results of FU based adjuvant therapy in stage II colon cancer

Number of patients	survival rate (%)*	p-value	Ref
1116	82 vs 80	NS	54
1565			56
-26% high risk*	75 vs 70	NS	
-74% low risk	87 vs 82	0,01	
318	72 vs 72	NS	57
1029	78 vs 70	0,007	58
3238	80 vs 77	0,06	55
576	84,9 vs 79,8	NS	11

\*high risk: obstruction, perforation, T4

Table 3. Results of FU based therapy in stage IV colon cancer

Schedule	Number of patients	Median survival	Ref
None vs FU/LV or FU/Lev	1365	8 vs 11-12	59
FOLFIRI/FOLFOX vs FOLFOX/FOLFIRI	220	20,6 vs 21,5	49
FU/LV/irinotecan vs FOLFOX	531	15,0 vs 19,5	13
FU/LV/irinotecan vs FU/LV/irinotecan/bevacizumab	1029	15,6 vs 20,3	61
FU/LV vs FU/LV/bevacizumab	500	17,9 vs 14,6	62
Cetuximab vs cetuximab/irinotecan	329	6,9 vs 8,6	12

### **Stage IV**

Although the treatment of stage IV patients is beyond the scope of this review on adjuvant 5-FU based chemotherapy, we would like to discuss it shortly. Palliative chemotherapy commonly increases the median survival of stage IV colon cancer patients from around 8 months without treatment to 12 months with FU/leucovorin therapy.<sup>59</sup> Better results could be achieved with the new generation of chemotherapeutic agents like irinotecan and oxaliplatin showing median survival periods of 20- 21 months.<sup>13,47,49</sup> Recently, the Dutch Colorectal Cancer Group finished inclusion of 820 patients in the CAIRO study, in which a sequential approach of 5-FU/LV, CPT-11 and oxaliplatin in phase III trials showed promising results in patients with metastatic disease, with a prolonged survival of more than 20 months. In a prospective study, Adam et al used a combination of FOLFOX/chronomodulated chemotherapy to obtain reduction of tumor load in patients with non-resectable liver metastases. After chemotherapy, 13.5% of patients were found to be resectable on re-evaluation and underwent a potentially curative resection. The 5-year survival was 35% in this group.<sup>60</sup> The development of drugs that inhibit signal transduction pathways have provided new opportunities in treating metastatic colon cancer. The concept of targeting tumor vasculature as a therapeutic strategy in human cancer was based on the observation that rapid growth of transplanted tumors was often preceded by a local increase in vascular density. This is called angiogenesis. One of the most potent mediators of angiogenesis is vascular endothelial growth factor (VEGF). VEGF mediates its effects by interacting with the membrane-bound tyrosine kinase receptors, thereby influencing angiogenesis. Bevacizumab is the recombinant humanized version of a murine antihuman VEGF monoclonal antibody. Several studies showed a beneficial effect of bevacizumab in combination with FU-based chemotherapy in patients with stage IV colon cancer.<sup>61,62</sup> In patients with metastatic disease the combination of bevacizumab and CPT-11/5-FU/LV should be considered as first-line treatment. Another example of anti-tumor therapy by inhibiting signal transduction is the inhibition of the epidermal growth factor receptor (EGFR). The EGFR signaling pathway regulates cell differentiation, proliferation, migration, angiogenesis and apoptosis, all of which become deregulated in cancer cells. Cetuximab is a chimeric IgG1 monoclonal antibody that binds to EGFR with high specificity and with a higher affinity than EGF, thereby blocking ligand-induced phosphorylation of EGFR. Cunningham et al showed that cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.<sup>12</sup> This study suggests that cetuximab may circumvent irinotecan

resistance. Studies on palliative treatment in stage IV colon cancer are summarized in table 3.

### **Treatment toxicity**

Dihydropyrimidine dehydrogenase (DPD), the first and rate-limiting enzyme in the three-step pathway of uracil and thymine catabolism, is also important in the degradation and inactivation of 5-FU.<sup>63</sup> DPD converts over 85% of the clinically administered 5-FU into the inactive metabolite dihydrofluorouracil, a process which takes place mainly in the liver.<sup>64</sup> Patients with a complete or near-complete deficiency of the enzyme do suffer from severe toxicity following the administration of standard doses of fluoropyrimidines, due to significantly increased and prolonged plasma levels of 5-FU.<sup>63-65</sup> The incidence of this pharmacogenetic syndrome in the general population is estimated to be as high as 3% and may be much more common than originally thought.<sup>66</sup> The use of fluoropyrimidines in patients with this metabolic defect is associated with a very high mortality.<sup>64</sup> The most common toxic reactions in patients without a known DPD deficiency to FU are nausea, vomiting, diarrhea, stomatitis, dermatitis and leucopenia. These reactions were rarely in the range of grade 3-4 toxicity in the study of Moertel et al.<sup>9</sup> This same study showed that 22% of patients experienced some degree of alopecia. A variety of neurological symptoms was reported by 18% of patients. These ranged from vague lightheadedness and emotional changes to disabling cerebellar ataxia. They usually abated when therapy was discontinued. 3% of patients developed severe leukopenia (WBC < 1000). The combination of FU with leucovorin increases some toxicity effects of FU, especially nausea; diarrhea and stomatitis are more often seen. The International Multicenter pooled Analysis of Colon Cancer (IMPACT) trial showed that severe toxic effects (WHO grade 4) occurred in fewer than 3% of cases with a combined FU/LV treatment.<sup>43</sup> Capecitabine and UFT, which are chemically related to FU showed significantly fewer side effects than FU.<sup>20,46</sup> One of the most frequent side effects of Capecitabine is the hand-foot syndrome in which the skin of hands and feet is affected. The FOLFOX regimen leads to a significantly higher rate of grade 3-4 leukopenia and neuropathy compared to FU/leucovorin alone (41 vs 5% and 12 vs 0,2%).<sup>11</sup> This neurotoxicity is a typical side effect of oxaliplatin and is usually reversible. The total prevalence of neurotoxicity in the FOLFOX study was 82%, of which 12 % consisted of a grade 3 toxicity. After 12 months follow up this rate decreased to 1,1% for grade 3 toxicity and 4,8% for grade 2 toxicity. The signal transduction inhibitors (bevacizumab and

cetuximab) do not cause major side effects in combination with the other agents. Bevacizumab caused grade 3 hypertension in 16% of FU/leucovorin/bevacizumab treated patients. In addition, proteinuria was seen more often with bevacizumab. There was also a disbalance in the incidence of arterial thrombotic events with an increased occurrence in the group with bevacizumab (10 vs 5%). No increase in grade 3 or 4 bleeding or venous thrombotic events was seen in bevacizumab treated patients. Two patients (2%) developed gastrointestinal perforation.<sup>62</sup> Cetuximab caused severe anaphylactic reactions in 1,2% of patients. An acne-like rash developed in about 80% of the patients, but grade 3 or 4 toxic effects on the skin were observed in only 9% of patients.<sup>12</sup>

### **Summary of current available strategies of adjuvant chemotherapy treatment**

Approximately 80% of the patients present with colon cancer in a stage that is considered to be potentially curable. Lymph node status is the most important predictor of outcome. The principal treatment for stage I, II and III tumors is surgery. In patients with stage II colon cancer, the use of adjuvant chemotherapy is debatable. The routine use of adjuvant chemotherapy is not supported by the ASCO in node-negative patients. However, there is indirect evidence of benefit for patients with high-risk stage II disease including bowel obstruction, perforation, T4 stage and less than 12 examined lymph nodes in the pathology report.<sup>40</sup> Systemic adjuvant therapy is standard treatment for stage III colon cancer and should consist of FU, leucovorin and oxaliplatin when possible.<sup>11</sup> Individual exceptions based on age and coexisting diseases are possible. Capecitabine and UFT are effective alternatives to FU/leucovorin in Stage III patients.<sup>20,46</sup> Fluoropyrimidines, irinotecan and oxaliplatin have efficacy in the management of metastatic colorectal cancer. Combinations of therapy can increase the median survival time from 8 to 20 months.<sup>49,67</sup> Neo-adjuvant treatment with the FOLFOX regimen is possible in patients with non-resectable stage IV disease, and can downsize non-resectable metastases to resectable metastases.<sup>60</sup> Targeting of the EGF-Receptor and VEGF-receptor is currently the most promising biological approach.

### **Future directions**

In adjuvant treatments, the group that does not benefit from therapy consists of patients who were qualified for adjuvant therapy but in spite of this still developed metastases and



patients who would never develop metastases in the spontaneous course of their disease (with or without this adjuvant treatment). The ratio between patients subjected to the side effects of therapy without any benefit and the patients who do benefit from chemotherapy is 5:1.<sup>68</sup> The great challenge for the future is to develop better selection criteria for adjuvant treatment, thereby reducing the group of patients who do not benefit at all from the treatment.

Better staging detects more lymph node positive patients and immunohistochemistry might help to detect stage II patients at higher risk. It is well known that the 5-year survival in node-negative patients is significantly higher when more lymph nodes have been examined.<sup>69</sup> Therefore, surgeons and pathologists should be stimulated to harvest and examine as much lymph nodes as possible. For adequate staging and treatment of patients with colon cancer, meticulous examination of at least 12 nodes by pathological analysis is warranted.<sup>32</sup> However, with a fat-clearance technique a mean number of 50 lymph nodes per specimen can be found.<sup>70</sup> In addition, intensive pathological examination of lymph nodes may reveal micrometastases that would be missed by routine hematoxylin & eosin (H&E) examination. Several authors have reported a decreased survival rate when nodal micrometastases are detected in CRC.<sup>71,72</sup> Based on the above mentioned studies, we can readily assume that the pathologist only samples a small part of the regional lymph nodes, and will certainly miss some lymph node metastases. The intensive staging techniques are time consuming, labor intensive and costly. The sentinel node procedure might select the right lymph nodes for intensive pathological examination, which will save time and money. The procedure has been validated in large studies.<sup>73-75</sup> It is a relatively simple procedure which only takes 5-10 minutes during surgery.

Besides ultrastaging, we should probably exploit our knowledge of tumor genetics and biology. A start in this area has already been made by treating stage IV colon cancer patients with signal transduction inhibitors like bevacizumab (anti-VEGF) and cetuximab (anti-EGFR).<sup>12,61</sup> These drugs still need to be tested in stage II and III patients.

Molecular biological factors might help to better select stage II + III patients at risk and those who are sensitive to and benefit from 5-FU based adjuvant therapy. This has already been done in breast cancer.<sup>76-78</sup> Wang et al found a combination of gene expression in colon cancer that predicted a 13-fold increased risk of relapse in stage II patients. These patients were selected for adjuvant therapy.<sup>79</sup> The results of this study still need to be evaluated in a larger study.

Genetically determined variability of the function of certain key enzymes has been shown to influence toxicity and response to certain types of chemotherapy and survival.<sup>80</sup> For example, patients with high thymidylate synthase gene expression profit from adjuvant therapy.<sup>6,81</sup> Patients with low thymidylate synthase expression and adjuvant therapy seem to have a worse prognosis than surgery alone.<sup>81</sup> This seems to be different from the situation in palliative 5-FU based chemotherapy.<sup>82</sup> Patients with colon tumors exhibiting high-frequency microsatellite instability do not benefit from FU-based chemotherapy.<sup>4</sup> Volk et al published a case report on an alternative chemotherapy regimen which was very well tolerated in a DPD-deficient patient.<sup>83</sup> More future trials should incorporate these genetic tumor variations in the choice of therapy.

In summary, better selection of patients should lead to a more targeted therapy in the future.

**Reference List**

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005; 55: 74-108.
2. Byers T, Gorsky R. Estimates of costs and effects of screening for colorectal cancer in the United States. *Cancer* 1992; 70: 1288-95.
3. Morikawa T et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. *Gastroenterology* 2005; 129: 422-8.
4. Ribic CM et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. *N Engl J Med* 2003; 349: 247-57.
5. Westra JL, Plukker JT, Buys CH, Hofstra RM. Genetic alterations in locally advanced stage II/III colon cancer: a search for prognostic markers. *Clin Colorectal Cancer* 2004; 4: 252-9.
6. Kornmann M et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. *Clin Cancer Res* 2003; 9: 4116-24.
7. Hermanek P. pTNM and residual tumor classifications: problems of assessment and prognostic significance. *World J Surg* 1995; 19: 184-90.
8. Cucino C, Buchner AM, Sonnenberg A. Continued rightward shift of colorectal cancer. *Dis Colon Rectum* 2002; 45: 1035-40.
9. Moertel CG et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. *N Engl J Med* 1990; 322: 352-8.
10. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. *Lancet* 2000; 355: 1588-96.
11. Andre T et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *N Engl J Med* 2004; 350: 2343-51.
12. Cunningham D et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004; 351: 337-45.
13. Goldberg RM et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 2004; 22: 23-30.
14. Hurwitz HI et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. *J Clin Oncol* 2005; 23: 3502-8.
15. Link KH et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-alpha. *Ann Surg* 2005; 242: 178-87.

16. Martenson JA, Jr. et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. *J Clin Oncol* 2004; 22: 3277-83.
17. Nordlinger B et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. *Lancet Oncol* 2005; 6: 459-68.
18. Poplin EA et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. *J Clin Oncol* 2005; 23: 1819-25.
19. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. *J Natl Cancer Inst* 2004; 96: 1128-32.
20. Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. *N Engl J Med* 2005; 352: 2696-704.
21. Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. *Nat Med* 1995; 1: 902-9.
22. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. *Nature* 1998; 396: 643-9.
23. Vogelstein B et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988; 319: 525-32.
24. Vogelstein B et al. Allelotype of colorectal carcinomas. *Science* 1989; 244: 207-11.
25. Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis. *Cancer Res* 2001; 61: 7369-74.
26. Gryfe R, Gallinger S. Microsatellite instability, mismatch repair deficiency, and colorectal cancer. *Surgery* 2001; 130: 17-20.
27. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. *Nature* 1993; 363: 558-61.
28. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. *Cell* 1996; 87: 159-70.
29. Thibodeau SN et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. *Cancer Res* 1996; 56: 4836-40.
30. Gryfe R et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. *N Engl J Med* 2000; 342: 69-77.

31. Lothe RA et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. *Cancer Res* 1993; 53: 5849-52.
32. Greene, F. L. Page D. L. Fleming I. D. et al. American Joint Committee on Cancer - Cancer staging handbook, TNM classification of malignant tumors. 129. 2002. New York: Springer.
33. Link KH et al. Colon cancer: survival after curative surgery. *Langenbecks Arch Surg* 2005; 390: 83-93.
34. Baron TH. Colonic stenting: technique, technology, and outcomes for malignant and benign disease. *Gastrointest Endosc Clin N Am* 2005; 15: 757-71.
35. Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. *Gut* 2005; 54: 1194-202.
36. Wiggers T et al. No-touch isolation technique in colon cancer: a controlled prospective trial. *Br J Surg* 1988; 75: 409-15.
37. van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. *Ann Oncol* 2000; 11: 385-91.
38. Laurie JA et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. *J Clin Oncol* 1989; 7: 1447-56.
39. Wolmark N et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. *J Natl Cancer Inst* 1988; 80: 30-6.
40. Benson AB, III et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. *J Clin Oncol* 2004; 22: 3408-19.
41. Schippinger W et al. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. *Br J Cancer* 2005; 92: 1655-62.
42. Kerr DJ. 5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? *Br J Cancer* 1989; 60: 807-8.
43. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. *Lancet* 1995; 345: 939-44.
44. O'Connell MJ et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. *J Clin Oncol* 1998; 16: 295-300.
45. Haller DG et al. Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089. *J Clin Oncol* 2005; 23: 8671-8.
46. Wolmark N et al. A phase III trial comparing oral UFT to FULV in stage II and II carcinoma of the colon: results of NSABP protocol c-06. {abstract 3508}. *Proc Am Soc Clin Oncol* 2004; 23: 247s.

47. Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. *J Clin Oncol* 2005; 23: 4553-60.
48. Saltz L et al. Irinotecan plus fluorouracil/leucovorin versus fluorouracil/leucovorin alone in stage II colon cancer (intergroup trial CALGB c89803) [abstract 3500]. *Proc Am Soc Clin Oncol* 2004; 23: 245s.
49. Tournigand C et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 2004; 22: 229-37.
50. van Cutsem E et al. Randomized phase III trial comparing infused irinotecan/5-fluorouracil/folinic acid versus 5-fluorouracil/folinic acid in stage III colon cancer patients (PETACC3). *Proc Am Soc Clin Oncol* 2005; 23: 1090s.
51. de Gramont A et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and III colon cancer: efficacy results with a median follow-up of 4 years. *Proc Am Soc Clin Oncol* 2005; 23: 246s.
52. Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith R. A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) And Oxaliplatin With 5-FU Plus LV For The Treatment Of Patients With Stages II And III Carcinoma Of The Colon [abstract 3500]. *ASCO Annual Meeting* 2005.
53. Arkenau H et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer: results of the safety and efficacy analysis. [abstract 3507]. *ASCO Annual Meeting* 2005.
54. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. *J Clin Oncol* 1999; 17: 1356-63.
55. Gray R et al. QUASAR:a randomized study of adjuvant chemotherapy vs observation including 3238 colorectal cancer patients [abstract 3501]. *Proc Am Soc Clin Oncol* 2004; 23: 245s.
56. Mamounas E et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). *J Clin Oncol* 1999; 17: 1349-55.
57. Moertel CG et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer. *J Clin Oncol* 1995; 13: 2936-43.
58. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. *Br J Cancer* 2001; 85: 1437-43.
59. Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. *Colorectal Cancer Collaborative Group. BMJ* 2000; 321: 531-5.

60. Adam R et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. *Ann Surg Oncol* 2001; 8: 347-53.
61. Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med* 2004; 350: 2335-42.
62. Kabbinnavar FF et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol* 2005; 23: 3706-12.
63. Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. *Cancer* 1991; 68: 499-501.
64. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. *Cancer Res* 1993; 53: 5433-8.
65. Van Kuilenburg AB et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. *Eur J Cancer* 1997; 33: 2258-64.
66. Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. *Oncology (Williston Park)* 1998; 12: 23-7.
67. Cunningham D et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. *Lancet* 1998; 352: 1413-8.
68. Mulder NH. [New oncolytic agents and immunomodulators and their application]. *Ned Tijdschr Geneesk* 2005; 149: 1438-40.
69. Le Voyer TE, Sigurdson ER, Hanlon AL, Mayer RJ, MacDonald JS, Catalano PJ, and Haller DG. Colon cancer survival is associated with increasing number of lymph nodes removed. A secondary analysis of Int-0089. *Proc.ASCO* 2000 19[925], 239. 1-1-2000.
70. Haboubi NY et al. The novel combination of fat clearance and immunohistochemistry improves prediction of the outcome of patients with colorectal carcinomas: a preliminary study. *Int J Colorectal Dis* 1998; 13: 99-102.
71. Greenson JK et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. *Cancer* 1994; 73: 563-9.
72. Liefers GJ et al. Micrometastases and survival in stage II colorectal cancer. *N Engl J Med* 1998; 339: 223-8.

73. Bilchik AJ et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. *Eur J Cancer* 2002; 38: 977-85.
74. Paramo JC et al. Intraoperative sentinel lymph node mapping in patients with colon cancer. *Am J Surg* 2001; 182: 40-3.
75. Saha S et al. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique--a multicenter trial. *Ann Surg Oncol* 2001; 8: 94S-8S.
76. 't Veer LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. *Nature* 2002; 415: 530-6.
77. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. *Nat Genet* 2003; 33: 49-54.
78. van de Vijver MJ et al. A gene-expression signature as a predictor of survival in breast cancer. *N Engl J Med* 2002; 347: 1999-2009.
79. Wang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. *J Clin Oncol* 2004; 22: 1564-71.
80. Lenz HJ. Pharmacogenomics and colorectal cancer. *Ann Oncol* 2004; 15 Suppl 4: iv173-iv177.
81. Edler D et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. *J Clin Oncol* 2002; 20: 1721-8.
82. Formentini A, Henne-Bruns D, Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. *Langenbecks Arch Surg* 2004; 389: 405-13.
83. Volk J et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. *Ann Oncol* 2001; 12: 569-71.



